Beaufort Securities reissued their speculative buy rating on shares of Amryt Pharma PLC (LON:AMYT) in a research report sent to investors on Wednesday. Beaufort Securities currently has a GBX 62 ($0.81) price target on the stock.

A number of other research firms have also recently commented on AMYT. Stifel Nicolaus reissued a buy rating and set a GBX 60 ($0.78) price target on shares of Amryt Pharma PLC in a report on Monday, April 24th. Shore Capital reaffirmed a house stock rating on shares of Amryt Pharma PLC in a report on Tuesday, March 28th.

Shares of Amryt Pharma PLC (AMYT) opened at 22.25 on Wednesday. The firm’s market capitalization is GBX 46.36 million. The stock has a 50 day moving average price of GBX 23.69 and a 200-day moving average price of GBX 21.47. Amryt Pharma PLC has a 52 week low of GBX 13.44 and a 52 week high of GBX 29.50.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/amryt-pharma-plc-lonamyt-stock-rating-reaffirmed-by-beaufort-securities/1461958.html.

About Amryt Pharma PLC

Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.

Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.